Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali 6-том 2-нөмір (2025)
THE IMPACT OF SACUBITRIL-VALSARTAN THERAPY IN PATIENTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION
Агабабян И.Р, Низамова Н.Г
Аңдатпа
Background: Over the past two decades, the number of heart failure cases has doubled worldwide, and heart failure with preserved ejection fraction (HFpEF) is becoming increasingly common, posing a significant challenge to public health. Currently, there are no effective treatments for this condition, making it crucial to conduct research. Materials and Methods: This study was conducted at the Сardiological centre of Samarkand region. It was an observational study that included 48 patients diagnosed with chronic HFpEF. Key clinical and laboratory parameters were recorded before and after treatment, and statistical analysis was performed using SPSS version 28.0. Differences were considered significant if p < 0.05. Results: The patients were divided into two groups: Group 1 (n=24) received sacubutril/valsartan therapy, and Group 2 (n=24) received valsartan monotherapy. After 16 weeks of treatment, a significant improvement in clinical and laboratory parameters was noted in patients receiving sacubutril/valsartan. The average decrease in systolic blood pressure (BP) was -10.3 ± 1.0 mmHg in the sacubutril/valsartan group compared to -6.4 ± 0.9 mmHg in the valsartan-only group (p<0.05). Functional class improvement of CHF (Congestive Heart Failure) according to the NYHA (New York Heart Association) classification was observed in 63% of patients in Group 1 versus 42% in Group 2 (p<0.05). Conclusions: These results confirm that sacubutril/valsartan combination therapy is more effective than valsartan monotherapy in patients with congestive heart failure. Treatment with sacubutril/valsartan has shown significant reductions in blood pressure, and hospitalization rates, as well as improvements in the functional status of patients. These findings suggest that this therapy could be a promising approach for treating patients with chronic heart failure, especially those with resistant hypertension.
Сердечная недостаточность с сохранённой фракцией выброса (ХСНсФБ), сакубутрил, валсартан, NYHA, систолического артериального давления (САД)Heart failure with preserved ejection fraction (HFpEF), sacubitril, valsartan, New York Heart Association (NYHA), systolic blood pressure (SBP)Saqlangan qon haydash fraksiyasi bilan yurak yetishmovchiligi (SQHFSYuY), sakubitril, valsartan, NYHA, sistolik qon bosimi (SQB).
Метадеректер дереккөзі: журналдың OAI-PMH архиві · Sindex толық мәтінді сақтамайды, дереккөзге сілтеме береді.